Italia markets close in 1 hour 32 minutes

Nanobiotix S.A. (0QAV.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
3,6100+0,0700 (+1,98%)
Al 01:21PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente3,5400
Aperto3,5700
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno3,5700 - 3,6100
Intervallo di 52 settimane3,5700 - 3,6100
Volume417
Media VolumeN/D
Capitalizzazione789.878
Beta (5 anni mensile)1,89
Rapporto PE (ttm)N/D
EPS (ttm)-1,3550
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Voting Rights and Shares Capital of the Company

    In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisable

  • GlobeNewswire

    NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

    Patients randomized in all planned major regions for pivotal phase 3 NANORAY-312 study with the United States added to Europe and AsiaNANORAY-312 now has sites activated across 80 sites globallyPhase 3 futility analysis expected in 2H 2023, with interim Phase 3 data expected in 2H 2024 PARIS and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expa

  • GlobeNewswire

    NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement

    PARIS and CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it has ended the liquidity contract signed on October 23, 2012 with Gilbert Dupont. The termination is effective from December 20th, 2022, after the close of Euronext market. On the termination date of this contrac